Oncology Pharma Reveals Strategic Designs for Corporation Growth and Focus OTC Markets:ONPH

SAN FRANCISCO, CA, March 16, 2021 (Globe NEWSWIRE) — by means of NewMediaWire – Oncology Pharma, Inc. (OTC: ONPH) revealed nowadays the Company’s designs for growth and advancement of its mental property and business enterprise product. Essential focal points include things like growth of its most cancers therapeutics by acquisition of license agreements and development of synergistic partnerships and expansion of other specialized niche therapeutics. Also, an important section of the Company’s strategic programs involve the objective of forming economical partnerships that permit the enhancement of licensed therapeutic brokers.   

Oncology Pharma’s spokesperson has mentioned, “We are seeking to grow our products under development in a way that they dovetail alongside one another and define our model. Now, we have recognized prospective financing sources for shorter phrase and midterm financings.”

ABOUT ONCOLOGY PHARMA, INC.

ONCOLOGY PHARMA, INC. (OTCPK: ONPH) (the “Corporation”) is at present engaging in investigate and advancement of therapeutics for oncology and prides alone for owning a environment-course Advisory Board that keeps the Organization in the forefront of producing technologies in cancer study, biotechnology, and healthcare.

Forward-On the lookout STATEMENTS

Certain of the issues mentioned in this announcement consist of forward-looking statements that involve material threats to and uncertainties in the Firm’s business that could result in genuine results to differ materially from all those predicted by the statements manufactured herein. Such threats and uncertainties incorporate dangers connected to licensing preparations and joint ventures, such as the need to negotiate the definitive agreements for the relationships possible failure to understand predicted benefits of business relationships and, expenses of giving funding to these business enterprise interactions. Other hazards and uncertainties relating to the Company incorporate, between other items, recent adverse operating dollars flows and a need for additional funding to finance our functioning approach the terms of any even further financing, which may possibly be remarkably dilutive and may perhaps include things like onerous conditions sudden expenses and working deficits, and decreased than predicted income and revenues uncertain willingness and capability of clients to undertake new systems and other variables that may affect additional sector acceptance adverse financial problems adverse outcomes of any legal proceedings the volatility of our functioning success and financial problem incapability to entice or retain capable senior management staff, which includes revenue and internet marketing staff our skill to set up and manage the proprietary mother nature of our technological know-how by way of the patent procedure, as very well as our capacity to quite possibly license from other people patents and patent applications vital to create products the Firm’s skill to put into action its prolonged vary business enterprise prepare for numerous applications of its technological know-how the Firm’s skill to enter into agreements with any vital marketing and/or distribution partners and with any strategic or joint undertaking companions the affect of levels of competition the obtaining and servicing of any necessary regulatory clearances applicable to applications of the Firm’s technological innovation management of advancement and, other hazards and uncertainties. This is not a solicitation to acquire or promote securities and does not purport to be an examination of the Firm’s economic situation.

CONTACTS:
For extra data, you should call the Oncology Pharma at:
Just one Sansome Street, Suite 3500
San Francisco, CA 94104
Phone: 415-869-1038 
Fax: 415-946-8801 
Web site: www.oncology-pharma.com
E-mail: [email protected]